Coherus Oncology (CHRS) valuation against sector peers: P/B 3.9, P/S 1.8.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	CHRS	Sector median	vs median
P/E	—	30.7 · n=158	—
P/B	3.9	4.0 · n=307	near the median
P/S	1.8	4.1 · n=302	55% below
EV/EBIT	—	25.8 · n=146	—
Free-cash-flow yield	—	1.4% · n=291	—
Dividend yield	0.00%	0.00% · n=362	—
Return on equity	−240.5%	−2.4% · n=308	—
Return on invested capital	—	0.6% · n=282	—
Gross margin	69.8%	63.3% · n=205	10% above
Net debt / EBITDA	—	1.27 · n=151	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	48.9	33.5	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	42.0	8.3	—	3.0%	1.9%	8/10
ABBVAbbVie	50.5	—	27.8	3.6%	2.9%	6/10
MRKMerck	148.8	8.1	—	4.0%	2.3%	8/10
UNHUnitedHealth	22.9	3.5	17.3	6.3%	2.2%	10/10
TMOThermo Fisher Scientific	37.6	4.9	35.6	2.9%	0.3%	9/10
AMGNAmgen	26.8	17.5	23.2	3.8%	2.1%	8/10
GILDGilead Sciences	—	16.3	—	6.5%	1.9%	5/10
ABTAbbott	40.7	3.7	32.9	3.5%	2.8%	6/10
PFEPfizer	41.5	1.9	—	7.0%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 09 Nov 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings